Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
HER-SAFE trial: what clinicians have said so far
Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction
- NCT05880160 ↗
- Completed
- University College, London
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on HER-SAFE (recovered HER2-targeted therapy-related cardiac dysfunction; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HER-SAFE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X |
The trial
ClinicalTrials.gov- Official title
- Randomised Control Trial for the Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction
- Phase
- Phase not applicable
- Status
- Completed
- Conditions
- Cardiotoxicity; HER2-positive Breast Cancer; Heart Failure; Cancer, Therapy-Related
- Interventions
- Phased withdrawal of heart failure medications
- Arms
- Treatment Withdrawal · Experimental
- Treatment Continuation · No intervention
- Enrollment
- 90
- Primary outcomes
- Relapse in Cardiotoxicity
- Sponsor
- University College, London with British Heart Foundation, University College London Hospitals, Royal Brompton & Harefield NHS Foundation Trust, Imperial College Healthcare NHS Trust, The Whittington Hospital NHS Trust, Barts & The London NHS Trust
- Start
- Jul 14, 2023
- Primary completion
- Jun 24, 2026
- Results posted
- No
- Registry record
- NCT05880160 · updated Sep 28, 2026
Publications
linked from the registry- Dowsing B, Dehbi HM, Chung R, Pedra J, Worn O, Artico J, Schmid P, Roylance R, Kellman P, Moon JC, Crake T, Westwood M, Ghosh A, Andres MS, Nazir MS, Lyon AR, Chen D, Walker M, Manisty CH. HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction. BMJ Open. 2025 Feb 5;15(2):e091917. doi: 10.1136/bmjopen-2024-091917. PubMed 39909533